Sponsored Content by Cerba ResearchReviewed by Louis CastelNov 22 2024
Image Credit: Christopher Burgstedt/Shutterstock.com
Experts from Cerba Research, a leading specialty laboratory solutions provider, recently attended the 31st European Society of Gene and Cell Therapy (ESGCT) Congress to share some of its most recent cell and gene therapy developments with an audience of industry experts, academia, sponsors and patient organizations. Each year, the ESGCT conference attracts key opinion leaders in gene and cell therapy from Europe and around the world, spotlighting recent breakthroughs and advancements in the field and highlighting novel techniques that are moving toward safe and curative treatments for both major and rare diseases. Events such as the ESGCT play a key role in helping to advance, improve and launch these novel treatments into clinical practice, as well as ensuring that cell and gene therapies are safe and effective.
Download the full article
Karthikeyan Devaraju, PhD Sr Scientist Cell & Gene Therapy Development
Karthikeyan Devaraju has over 15 years’ experience in the regenerative medicine and advanced therapies (diverse cell and gene therapies). His expertise spans stem cells, cell fate engineering, gene delivery systems, product development and both process and analytical development / optimization using diverse technology platforms. He received his PhD in Stem Cells and Neurology from Lund University. He has held various scientific positions in academic research institutions, bio-pharma and CDMOs.
About Cerba Research
Cerba Research is a leading specialty laboratory services provider with the capacity and breadth of a global central laboratory network. Our highly qualified scientists provide insight on the latest biomarkers, assays and testing approaches and develop innovative solutions for unique challenges across all research phases, to pharmaceutical, biotechnology, medical device, government, public health, and CRO organizations. Cerba Research’s extensive capability in laboratory testing and global logistics including Cell & Gene Therapy, Bioanalysis, Flow Cytometry, HistoCytopathology, and Next Generation Sequencing, enables us to drive operational agility at scale in a wide range of therapeutic areas, with recognized expertise in Virology, Immunology, Oncology and Cell & Gene Therapy. Cerba Research is part of the Cerba HealthCare Group with 15,000 employees on five continents, driven to advance diagnosis and health.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.